U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06893926) titled 'Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction' on March 06.
Brief Summary: S100B protein is a biomarker that increases following central nervous system (CNS) damage. Measuring this protein's levels may allow for the early identification of infants at high risk for developmental abnormalities, such as fetal growth restriction (FGR), even on the first day of life, in a non-invasive manner. Early detection could enable timely interventions and rehabilitation, potentially improving the child's prognosis and long-term outcomes. This study investigates two groups of full-term pregnancies: a study group ...